Edgar Specker

Head of Core Facility

Leibniz-Forschungsinstitut für Molekulare Pharmakologie

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Edgar Specker is the Head of Core Facility at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie in Germany. His research focuses on the development of small molecules targeting various enzymatic pathways, particularly involving tryptophan hydroxylase and its inhibitors, as well as regulatory T cell generation. Recent publications highlight his work on the pharmacological properties and safety profiles of novel compounds in relation to cancer metastasis and pulmonary arterial hypertension.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

Ruth Brenk

Professor at University of Bergen

University of Bergen

NORWAY

View details

Julia K. Polansky

Prof, Group leader

Charité - Universitätsmedizin Berlin

GERMANY

View details

Georg Hansmannn

Lead Attending, Professor

Hannover Medical School

GERMANY

View details

Dirk Pleimes

UNITED STATES

View details

Michael Bader

Professor

Charité - Universitätsmedizin Berlin

GERMANY

View details

Philip Gribbon

ITMP Head Discovery Research

Fraunhofer-Gesellschaft

GERMANY

View details

Lars Winkler

Head of Cell Culture, Senior Scientist, Project manager

EPO Berlin-Buch GmbH

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Edgar Specker

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Generation of Regulatory T Cells From Human Memory CD4<sup>+</sup>T Cells by Upregulation of Naked Cuticle Homolog 2

Selectivity and Safety Characterization of a Xanthine–Imidazothiazole Lead Structure: a Novel Tryptophan Hydroxylase Inhibitor of Peripheral Serotonin Synthesis

Inhalation of the Novel Tryptophan Hydroxylase 1 Inhibitor TPT-004 Alleviates Pulmonary Arterial Hypertension

TPT‐004, a Next‐Generation Inhibitor of Tryptophan Hydroxylase, Ameliorates Pulmonary Arterial Hypertension in Rats

Design, Quality and Validation of the EU-OPENSCREEN Fragment Library Poised to a High-Throughput Screening Collection

Identification of drug-like molecules targeting the ATPase activity of dynamin-like EHD4

Novel Tryptophan Hydroxylase Inhibitor TPT-001 Reverses PAH, Vascular Remodeling, and Proliferative-Proinflammatory Gene Expression

Structure-Based Design of Xanthine-Imidazopyridines and -Imidazothiazoles as Highly Potent and In Vivo Efficacious Tryptophan Hydroxylase Inhibitors

Small Molecules Targeting Human UDP‐GlcNAc 2‐Epimerase

Discovery of tetrazolo-pyridazine-based small molecules as inhibitors of MACC1-driven cancer metastasis

Collaborators (7)

Ruth Brenk

Julia K. Polansky

Georg Hansmannn

Dirk Pleimes

Michael Bader

Philip Gribbon

Lars Winkler

Make your next move.